The approval allows Vivos to begin in-house manufacturing of IsoPet and supports broader commercialization of its veterinary cancer treatment platform. ・Vivos Inc. (USOTC:RDGL) received a Washington ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results